杭州智鹤丹谷生物医药

Zhihe Dangu is a clinical-stage biotechnology company headquartered in Hangzhou, China, focusing on the advancement of non-viral CAR-T cell therapies. The company utilizes a proprietary transposon-based gene insertion platform to develop treatments for various cancers, aiming to provide safer and more affordable alternatives to traditional viral-vector-based therapies. Their lead candidate, ZH-001, is a non-viral CD19-targeted CAR-T therapy currently undergoing clinical evaluation for hematological malignancies. Beyond liquid tumors, Zhihe Dangu is actively expanding its pipeline to include candidates for solid tumors, such as those targeting GPC3. The company represents a growing segment of the Chinese biotech industry focused on manufacturing innovation and accessibility in cell therapy.